The China factor: US pharma group campaigns for increased competitiveness

Core Insights - The US healthcare industry must consider systemic changes to maintain its innovative leadership amid increasing competition from China [1][4] - Key discussions at a recent event highlighted China's rapid advancements in the healthcare sector, particularly in the pace and cost of Phase I trials and the share of innovative therapies [2] Group 1: Innovation and Competition - Industry experts emphasize the need for the US to streamline the process of drug development to remain competitive [3] - The US is currently losing ground in mRNA vaccine development, with 46% of this innovation now occurring in China [5] - The US healthcare sector is urged to enhance engagement with patients and improve the drug approval ratio to foster innovation [3] Group 2: Economic Dependencies and Global Landscape - Chinese biotechs rely heavily on US capital and market access to sustain their economic viability [6] - The predictability of government long-term plans and the skilled workforce in China are cited as key factors contributing to its success in the healthcare industry [6] - The evolving international landscape presents opportunities for learning and adaptation within the global healthcare sector [6]